Revenue surged 89.7% year-over-year to $33.9M in Q2 2026, with gross margin expanding to 45.0%, yet operating margin remains deeply negative at -25.7% due to R&D and SG&A costs of $24.0M exceeding gross profit of $15.3M.
Ambiq Micro, Inc. (AMBQ) annual income statement — 5-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'21 | Dec'20 |
|---|
| Sales/Revenue | 117.84M | 72.51M | 76.07M | 65.54M | 91.01M | 50.97M |
| Revenue Growth % | 63.42% | -4.67% | 16.07% | -27.99% | 78.54% | - |
| Cost of Goods Sold | 65M | 46.82M | 51.78M | 46.1M | 60.24M | 29.4M |
| COGS % of Revenue | - | 64.57% | 68.07% | 70.34% | 66.19% | 57.68% |
| Gross Profit | 52.84M | 25.7M | 24.29M | 19.44M | 30.77M | 21.57M |
| Gross Margin % | 44.84% | 35.43% | 31.93% | 29.66% | 33.81% | 42.32% |
| Gross Profit Growth % | - | 5.78% | 24.95% | -36.81% | 42.61% | - |
| Operating Expenses | 95.23M | 66.84M | 64.9M | 70.76M | 55.87M | 41.79M |
| OpEx % of Revenue | - | 92.17% | 85.32% | 107.97% | 61.39% | 81.98% |
| Selling, General & Admin | 39.95M | 33.15M | 27.74M | 26.74M | 19.13M | 14M |
| SG&A % of Revenue | - | 45.72% | 36.46% | 40.81% | 21.01% | 27.47% |
| Research & Development | 55.28M | 33.69M | 37.17M | 44.02M | 36.11M | 27.79M |
| R&D % of Revenue | - | 46.45% | 48.86% | 67.17% | 39.67% | 54.51% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 636K | 0 |
| Operating Income | -42.39M | -41.14M | -40.61M | -51.32M | -25.1M | -20.21M |
| Operating Margin % | -35.97% | -56.74% | -53.39% | -78.31% | -27.58% | -39.66% |
| Operating Income Growth % | - | -1.31% | 20.87% | -104.46% | -24.17% | - |
| EBITDA | -34.24M | -33.93M | -34.37M | -43.61M | -22.49M | -18.29M |
| EBITDA Margin % | -29.05% | -46.79% | -45.18% | -66.54% | -24.71% | -35.88% |
| EBITDA Growth % | -0.95% | 1.28% | 21.19% | -93.89% | -22.96% | - |
| D&A (Non-Cash Add-back) | 5.17M | 7.21M | 6.25M | 7.72M | 2.61M | 1.93M |
| EBIT | -34.99M | -36.42M | -39.63M | -50.3M | -24.46M | -20.21M |
| Net Interest Income | 0 | 0 | 0 | 0 | 43K | -4.58M |
| Interest Income | 0 | 0 | 0 | 0 | 43K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 4.58M |
| Other Income/Expense | 7.39M | 4.72M | 980K | 1.02M | -216K | -4.98M |
| Pretax Income | -34.99M | -36.42M | -39.63M | -50.3M | -25.32M | -25.2M |
| Pretax Margin % | -29.7% | -50.23% | -52.1% | -76.75% | -27.82% | -49.43% |
| Income Tax | 27K | 40K | 28K | 30K | 25K | 25K |
| Effective Tax Rate % | -0.08% | -0.11% | -0.07% | -0.06% | -0.1% | -0.1% |
| Net Income | -35.02M | -36.46M | -39.66M | -50.33M | -25.34M | -25.22M |
| Net Margin % | -29.72% | -50.28% | -52.14% | -76.8% | -27.85% | -49.48% |
| Net Income Growth % | 2.65% | 8.07% | 21.2% | -98.61% | -0.48% | - |
| Net Income (Continuing) | -35.02M | -36.46M | -39.66M | -50.33M | -25.34M | -25.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.44 | -4.57 | -3.13 | -5.00 | -0.10 | -1.85 |
| EPS Growth % | 28.69% | -46.01% | 37.4% | -4900% | 94.59% | - |
| EPS (Basic) | - | -4.57 | -3.13 | -5.00 | -0.10 | -1.85 |
| Diluted Shares Outstanding | 24.27M | 7.98M | 13.61M | 10.45M | 248.89M | 13.61M |
| Basic Shares Outstanding | 24.27M | 7.98M | 13.54M | 10.45M | 248.89M | 13.61M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Quick answers to the most common questions about buying AMBQ stock.
For fiscal year 2025, Ambiq Micro, Inc. (AMBQ) reported total revenue of $72.5M. This represents a 42.3% increase compared to $51.0M in 2020.
Ambiq Micro, Inc. (AMBQ) reported a net loss of $36.5M for the fiscal year ending 2025.
Ambiq Micro, Inc. (AMBQ) reported an operating income of $-41.1M, resulting in an operating profit margin of -56.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Ambiq Micro, Inc. (AMBQ) generated $25.7M in gross profit for the year, representing a gross profit margin of 35.4%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses and thin gross margins
Metrics are mathematically derived from official filings.
Inflection in Revenue Trajectory
Revenue surged 89.7% year-over-year to $33.9M in 2026Q2, marking the fifth consecutive quarter of growth, according to the latest quarterly report, reversing prior contraction.
The 2026Q2 revenue of $33.9M represents a dramatic acceleration from the $15.2M reported in 2024Q1, with sequential growth of 35% from 2026Q1's $25.1M. This inflection appears driven by the Atomiq edge AI platform gaining commercial traction, as management's raised guidance for Q3 ($36-37M) suggests sustained momentum. However, the sustainability of this growth hinges on design win conversions and the cyclicality of the wearable market, which previously caused a -4.67% TTM contraction.
Gross Margin Expansion Amidst Structural Constraints
Gross margin improved to 45.0% in 2026Q2 from 17.2% in 2024Q4, as reported in financial statements, yet remains below the 53.6% peer average, indicating pricing and cost pressures.
The gross margin recovery from the anomalous 17.2% in 2024Q4 to 45.0% in 2026Q2 suggests improved product mix and scale benefits, but the level still lags peers like SiTime (53.6%) and MACOM (54.9%). This may reflect aggressive pricing to win designs in the competitive wearable market or higher testing costs inherent to subthreshold technology. Investors should monitor whether gross margin can expand further as volumes scale, or if it remains capped by structural factors.
Operating Leverage Still Elusive
Despite revenue growth, operating margin improved to -25.7% in 2026Q2 from -65.7% in 2025Q1, but fixed R&D and SG&A costs continue to outpace gross profit, as per the income statement.
Operating income improved to -$8.7M in 2026Q2 from -$10.3M in 2025Q1, but the operating margin of -25.7% remains deeply negative. R&D and SG&A combined totaled $24.0M in 2026Q2, exceeding gross profit of $15.3M, indicating that the company is still investing heavily ahead of revenue. The path to operating breakeven requires either continued rapid revenue growth or a slowdown in expense growth, which appears unlikely given the R&D intensity needed to maintain the technology lead.
Losses Narrow but SBC Distorts EPS
Net loss narrowed to -$7.1M in 2026Q2 from -$10.2M in 2026Q1, but stock-based compensation of $6.9M in 2026Q2, as disclosed, represents a significant non-cash expense affecting reported EPS.
The reported EPS of -$0.32 in 2026Q2 includes $6.9M in stock-based compensation, which is a substantial portion of the net loss. Excluding SBC, the adjusted loss would be smaller, but the cash burn remains a concern. The company's reliance on equity compensation suggests a need to conserve cash, and investors should monitor the dilution impact as the company continues to fund operations through equity raises.
R&D and SG&A Outpace Revenue
R&D and SG&A expenses totaled $24.0M in 2026Q2, exceeding gross profit of $15.3M, as per the income statement, indicating a high fixed-cost structure typical of fabless semiconductor firms.
R&D spending of $14.1M in 2026Q2 represents 41.6% of revenue, reflecting the company's commitment to advancing its subthreshold technology and Atomiq platform. SG&A of $9.9M is also elevated, likely due to sales and marketing efforts to secure design wins. While these investments are necessary for growth, they currently outpace revenue generation, leading to negative operating margins. Management's expense discipline will be critical as the company scales.
2026Q2 Marks a Turning Point
The 2026Q2 quarter stands out as a definitive inflection, with revenue up 89.7% year-over-year and gross margin expanding to 45.0%, according to the latest earnings report, reversing prior declines.
This quarter reversed the prior trend of revenue contraction and margin compression, driven by the edge AI strategy gaining traction. The sequential revenue growth of 35% from 2026Q1 and management's raised guidance suggest that the inflection is durable. However, the lasting impact depends on whether the company can translate this growth into profitability, as operating losses remain substantial. The fifth consecutive quarter of growth indicates a positive trajectory, but the path to breakeven is still unclear.
What Could Invalidate the Base Case
Despite the revenue surge, TTM operating margin of -56.7% and net margin of -50.3% persist, as per the income statement, suggesting growth is purchased at a high cost.
The rapid growth may not translate into profitability if gross margins remain capped near 45% due to competitive pricing or product mix, limiting operating leverage. The company's reliance on external funding is a risk if growth decelerates, as the negative cash flow from operations could force dilutive raises. Additionally, the modest gross margin relative to peers suggests structural cost disadvantages that may not improve with scale, warranting close monitoring of margin trends.